The URL can be used to link to this page

Home My WebLink AboutGrants/CJAB - Pennsylvania Commission on Crime and Delinquency (2)1. Recipient Name and Address Franklin County Commissioners 272 North 2nd Street Chambersburg, Pennsylvania 17201-1642 2. PCCD Grant Award Number 2025/2026-OG-SU-47422 3. Total Award Amount: $228,918.00 4. Project Title "Franklin County Improving Justice System Responses" 5. Project Period 1/1/2026 - 6/30/2027 6. Special Conditions This grant is approved subject to such conditions or limitations as set forth below: 1. This award will become effective when an appropriate official of your organization accepts it by signing and attaching the signed copy to Egrants. 2. This subgrant is offered on the condition that you comply in administering your program with: a. All of the representations contained in your application, as amended b. PCCD's Applicant's Manual c. For federally funded awards, all applicable federal grant guidelines including, but not limited to, 2 CFR 200 and the special conditions listed on PCCD's federal award(s) applicable to this subaward. PCCD's federal awards can be found at http://www.pccd.pa.gov/Funding/Pages/PCCD- Federal-Awards.aspx Continued on the Following Page(s) 7. Funding Details Fund Source #1 2025 OG Award Amount: $115,959.00 2025 OG Project Period: 1/1/2026 - 9/29/2026 2025 OG ALN: 93.788 2025 OG Federal Award #: H79TI087839 Fund Source #2 2026 OG Award Amount: $112,959.00 2026 OG Project Period: 9/30/2026 - 6/30/2027 2026 OG ALN: 93.788 2026 OG Federal Award #: H79TI087839 8. Fiscal Contact Mr. Daniel Hoon dhoon@pa.gov 717-265-8473 9. Program Contact Ms. Jennifer Bowser jennbowser@pa.gov 717-257-6255 10. Name and Title of Approving Official 11. Name and Title of Authorized Recipient 12. Signature of Approving Official Date 13. Signature of Authorized Recipient Grant Award Notification Page 1 of 3 P.O. Box 1167 | Harrisburg , PA 17108-1167 | 1 (800) 692-7292 | F (717) 783-7713 | https://www.pccd.pa.gov /Derin Myers/ Derin Myers Director, Office of Financial Management and Administration Electronically Signed: 03/02/2026 10:06 AM Derin Myers PCCD Grant Award Number: 2025/2026-OG-SU-47422 SPECIAL CONDITIONS 3. Prior to reporting consulting expenditures a PMR must be submitted with consultant detail as well as Conference travel and training details. 4. 1. Only medications approved by the U.S. Food and Drug Administration (FDA) for treatment of opioid use disorder and opioid overdose can be purchased with SOR funds. 2. Funds may not be expended through the grant or a subaward by any agency which would deny any eligible client, patient or individual access to their program because of their use of FDA-approved medications for the treatment of 26 substance use disorders (e.g., methadone, buprenorphine products including buprenorphine/naloxone combination formulations and buprenorphine monoproduct formulations, naltrexone products including extended-release and oral formulations or long acting products such as extended release injectable or implantable buprenorphine.) Specifically, patients must be allowed to participate in methadone treatment rendered in accordance with current federal and state methadone dispensing regulations from an Opioid Treatment Program and ordered by a physician who has evaluated the client and determined that methadone is an appropriate medication treatment for the individual’s opioid use disorder (OUD). Similarly, medications available by prescription or office-based implantation must be permitted if it is appropriately authorized through prescription by a licensed prescriber or provider. In all cases, medications for opioid use disorder (MOUD) must be permitted to be continued for as long as the prescriber or treatment provider determines that the medication is clinically beneficial. Recipients must assure that clients will not be compelled to no longer use MOUD as part of the conditions of any programming if stopping is inconsistent with a licensed prescriber’s recommendation or valid prescription. 3. Funds may not be used to make direct payments to individuals to enter treatment or continue to participate in prevention or treatment services (See 42 U.S.C. § 1320a-7b). 4. SAMHSA requires that MOUD is made available to those diagnosed with OUD. MOUD includes FDA- approved treatments such as methadone, buprenorphine products, including single-entity buprenorphine products, buprenorphine/naloxone tablets, films, buccal preparations, long-acting injectable buprenorphine products, and injectable extended-release naltrexone. 5. SOR grant funds must be used to provide services or practices that have a proven evidence base and are appropriate for the populations of focus. 6. SOR funds may not be used for services that can be supported through other accessible sources of funding such as other federal discretionary and formula grant funds, (e.g. Department of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Health Resources and Services Administration, and Substance Abuse and Mental Health Services Administration, Department of Justice (Office of Justice Programs and Bureau of Justice Assistance)) and non-federal funds, third party insurance, and sliding scale self-pay among others. 7. SOR funds for treatment and recovery support services may be used only to provide services to individuals that specifically address opioid or stimulant misuse issues. If either an opioid or stimulant misuse problem or history exists concurrently with other substance use, all substance use issues may be addressed. Individuals who have no history of or no current issue with opioids or stimulants misuse shall not receive treatment or recovery services with SOR grant funds. Grant Award Notification Page 2 of 3 P.O. Box 1167 | Harrisburg , PA 17108-1167 | 1 (800) 692-7292 | F (717) 783-7713 | https://www.pccd.pa.gov 8. SOR funds may not be used to provide incentives to any Health Care Professional for receipt of any type of Professional Development Training. 9. Grant funds may not be used, directly or indirectly, to purchase, prescribe, or provide marijuana or treatment using marijuana. Treatment in this context includes the treatment of opioid use disorder and stimulant use disorder. Grant funds also cannot be provided to any individual who or organization that provides or permits marijuana use for the purposes of treating substance use or mental disorders. See, e.g., 45 C.F.R. § 75.300(a) (requiring HHS to “ensure that Federal funding is expended . . . in full accordance with U.S. statutory . . . requirements.); 21 U.S.C. § 812(c)(10) and 841 (prohibiting the possession, manufacture, sale, purchase or distribution of marijuana). This prohibition does not apply to those providing such treatment in the context of clinical research permitted by the DEA and under an FDA-approved investigational new drug application where the article being evaluated is marijuana or a constituent thereof that is otherwise a banned controlled substance under federal law. 10. SOR funds may not be used for promotional items such as clothing and commemorative items such as pens, mugs/cups, folders/folios, lanyards and conference bags. 11. In accordance with Division H, Title II of the Consolidated Appropriations Act, 45 CFR Part 75, and 2 CFR Part 200, no funding shall be used to: a. Pay for any lease beyond the project period; b. Pay for the purchase or construction of any building or structure to house any part of the program; c. Provide residential or outpatient treatment services when the facility has not yet been acquired, sited, approved, and met all requirements for human habitation and services provision; d. Make direct payments to individuals to induce them to enter prevention or treatment services; e. Make direct payment to individuals to encourage attendance and/or attainment of prevention or treatment goals. 5. Project is split into two 9 month periods: 1/1/2026 - 9/29/2026 for Year 1 and 9/30/2026 - 6/30/2027 for Year 2. Unexpended funds budgeted in the first nine-month period cannot be carried over into the second nine-month period. Grant Award Notification Page 3 of 3 P.O. Box 1167 | Harrisburg , PA 17108-1167 | 1 (800) 692-7292 | F (717) 783-7713 | https://www.pccd.pa.gov